Cargando…
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important enzyme...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Society for the Study of Obesity
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526285/ https://www.ncbi.nlm.nih.gov/pubmed/34518444 http://dx.doi.org/10.7570/jomes21033 |